Phathom Pharmaceuticals Inc. (PHAT)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
Phathom Pharmaceuticals, Inc. (PHAT) Q2 2026 Earnings Call Transcript
Phathom Pharmaceuticals, Inc. (PHAT) Q2 2026 Earnings Call Transcript
Phathom Pharmaceuticals Q2 Earnings Call Highlights
Phathom Pharmaceuticals NASDAQ: PHAT reported second-quarter 2026 revenue growth of 88% year over year and said it achieved positive operating profit excluding stock-based compensation for the first time in its history, reaching the milestone one quarter ahead of its prior plan.
Phathom Pharmaceuticals, Inc. (PHAT) Reports Break-Even Earnings for Q2
Phathom Pharmaceuticals, Inc. (PHAT) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.79 per share a year ago.
Phathom Pharmaceuticals Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| BZ Brandon Zatopek Commonwealth Equity Services LLC | 22,535 | $244,500 | $188,054.57 | -$56,445.43 | -23.09% |
| BG Bart Gancher Intech Investment Management LLC | 11,388 | $94,930.32 | $97,367.4 | $2,437.08 | 2.57% |
| JM John Malone Amundi | 4,513 | $151,684.39 | $38,676.41 | -$113,007.98 | -74.5% |
 Point72 Asset Management LP Point72 Asset Management LP | 1.02M | $11.09M | $9.79M | -$1.3M | -11.71% |
| PF Phillip Fitzsimmons Hennion & Walsh Asset Management Inc. | 327,278 | $4.22M | $2.74M | -$1.48M | -35.13% |
Phathom Pharmaceuticals Inc. (PHAT) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Phathom Pharmaceuticals Inc. ever had a stock split?
Phathom Pharmaceuticals Inc. Profile
| Biotechnology Industry | Healthcare Sector | Steven L. Basta CEO | NASDAQ (NGS) Exchange | 71722W107 CUSIP |
| US Country | 371 Employees | - Last Dividend | - Last Split | 25 Oct 2019 IPO Date |
Overview
Phathom Pharmaceuticals, Inc. is a biopharmaceutical company primarily engaged in the development and commercialization of novel treatments for gastrointestinal diseases. Backed by the rights to market their products in the United States, Europe, and Canada, Phathom Pharmaceuticals is at the forefront of addressing unmet medical needs in this domain. The company's strategic focus is on leveraging innovative research methodologies to offer viable and effective solutions for conditions associated with acid secretion in the stomach. Incorporated in 2018, Phathom Pharmaceuticals is headquartered in Florham Park, New Jersey, positioning itself as a key player in the healthcare sector by pushing the boundaries of medical research within the gastrointestinal field.
Products and Services
- Investigational Potassium-Competitive Acid Blocker (P-CAB)
- Vonoprazan for Erosive Gastroesophageal Reflux Disease (GERD)
- Vonoprazan in Combination with Antibiotics for Helicobacter pylori Infection
This groundbreaking product represents Phathom Pharmaceuticals' cutting-edge approach to gastroenterology. As a Potassium-Competitive Acid Blocker (P-CAB), it is designed to offer a new mechanism for controlling stomach acid secretion, differentiating it from traditional treatments. The primary intent of this investigational drug is to provide a more efficient and possibly safer alternative for patients suffering from conditions arising from excessive acid production in the stomach.
Vonoprazan, another critical part of Phathom Pharmaceuticals' product line, is in development to treat erosive gastroesophageal reflux disease (GERD). This condition, which affects a significant portion of the population, leads to discomfort and potential complications due to stomach acid damaging the esophagus. By focusing on this P-CAB, Phathom Pharmaceuticals aims to bring about a significant improvement in the treatment landscape for GERD patients, providing relief and better health outcomes.
Building on the versatility of vonoprazan, Phathom Pharmaceuticals is exploring its potential in combination with antibiotics to treat Helicobacter pylori infections. This type of infection is a common cause of ulcers and can lead to more serious gastric issues if left untreated. The collaboration of vonoprazan with antibiotics signifies a robust approach to eradicate H. pylori, offering a comprehensive treatment path that could revolutionize the management of the infection and its related conditions.
